Marc Fagel Joins SEDA Experts LLC

SEDA Experts LLC announced that Marc Fagel joined the firm on September 8, 2026. SEDA Experts LLC is an expert witness firm that provides financial expert witness services. Mr. Fagel joined as a managing director, according to citybiz. This move expands the firm's securities enforcement and regulatory expertise, as reported by The Manila Times.

The details

Marc Fagel held a senior position at the Securities and Exchange Commission (SEC). He was a former SEC Regional Director, according to citybiz. His appointment to SEDA Experts LLC was announced on September 8, 2026. SEDA Experts LLC describes itself as a leading expert witness firm. It specializes in financial expert witness services. Mr. Fagel's role as managing director will contribute to the firm's capabilities in securities enforcement and regulatory matters.

As a former senior official at the SEC, Mr. Fagel possesses direct experience with the agency's enforcement mechanisms and regulatory frameworks. The SEC is responsible for protecting investors, maintaining fair, orderly, and efficient markets, and facilitating capital formation. This mission is primarily achieved through the enforcement of federal securities laws. The SEC's enforcement division investigates potential violations of these laws, which can range from accounting fraud and insider trading to market manipulation and disclosure failures. Investigations often involve gathering evidence, issuing subpoenas, taking testimony, and, if warranted, recommending enforcement actions to the Commission. These actions can result in civil penalties, disgorgement of ill-gotten gains, and injunctions against future misconduct. Mr. Fagel's tenure would have provided him with an understanding of these processes from within the regulatory body, including the criteria for initiating investigations, the evidentiary standards required for successful enforcement, and the negotiation of settlements.

His role as a Regional Director implies oversight of SEC activities within a specific geographic area, involving direct management of enforcement staff and regulatory initiatives. This operational experience provides a practical perspective on how SEC policies are implemented and how enforcement cases are built and prosecuted. For an expert witness firm like SEDA Experts LLC, this background is valuable because it offers insight into the regulatory mindset and the technical aspects of securities law application. Expert witnesses often provide testimony in legal proceedings, explaining complex financial or regulatory issues to judges and juries. Mr. Fagel's experience could enable him to articulate the intricacies of SEC regulations and enforcement actions with authority and clarity, drawing on his direct involvement in such matters.

Why it matters

Mr. Fagel's background at the SEC suggests an enhancement of SEDA Experts LLC's capabilities in securities law, particularly in areas related to enforcement and regulatory compliance. The SEC and the Food and Drug Administration (FDA) recently established a framework for regulatory collaboration through a Memorandum of Understanding (MOU), according to The National Law Review. This framework supports regulatory and enforcement cooperation between the two agencies. The collaboration focuses on areas such as disclosure, insider trading, and prediction markets, particularly relevant to life sciences companies.

This inter-agency collaboration mechanism is significant because it formalizes information sharing and coordinated enforcement efforts between two powerful federal agencies. The FDA regulates the safety and efficacy of drugs, medical devices, and other biological products, while the SEC oversees the financial markets where life sciences companies raise capital and trade their securities. Historically, information asymmetry or misrepresentation in the context of drug trials or product approvals could lead to market manipulation or investor fraud. For instance, a company might selectively disclose positive trial results while withholding negative ones, impacting its stock price. The MOU aims to mitigate such risks by creating a structured channel for communication and joint action. This means that if the FDA uncovers information relevant to a company's financial disclosures or potential insider trading, it can share that with the SEC, and vice-versa. This enhanced coordination can lead to more robust investigations and enforcement actions against companies or individuals who exploit regulatory information for financial gain.

Mr. Fagel's expertise may be particularly relevant to firms navigating these inter-agency dynamics. His experience within the SEC provides him with an understanding of how the agency approaches enforcement, including its interpretation of disclosure requirements and its methods for detecting insider trading. In the context of the FDA-SEC MOU, his knowledge of SEC procedures could be critical for life sciences companies seeking to ensure compliance with both FDA regulations and SEC disclosure obligations. For example, he could advise on how to structure public announcements regarding clinical trial results to satisfy both agencies' requirements, or how to implement internal controls to prevent insider trading based on pre-market approval information. His insights into the SEC's investigative techniques and its legal interpretations could help companies proactively identify and address potential compliance gaps, thereby reducing their exposure to enforcement risks. His experience could assist clients facing complex regulatory issues, especially those at the intersection of financial markets and public health regulations.

What to watch

Future announcements from SEDA Experts LLC may detail specific areas where Mr. Fagel's expertise will be applied, potentially including new service offerings or specialized practice groups focused on SEC enforcement, regulatory compliance, or inter-agency matters. Any new engagements or publications from the firm involving Mr. Fagel could provide further insight into how his specific experience is being leveraged. For instance, if SEDA Experts LLC begins to publish analyses or host webinars on topics related to FDA-SEC collaboration or life sciences disclosure, it would indicate a direct application of his specialized knowledge. The firm's client roster may also evolve to include more entities operating in highly regulated sectors, such as biotechnology or pharmaceuticals, seeking guidance on complex regulatory intersections. Additionally, observing the types of cases in which Mr. Fagel is retained as an expert witness could reveal the specific areas of securities law where his insights are most sought after, such as complex fraud, market manipulation, or compliance failures related to public company disclosures. This could include cases involving allegations of insider trading or misrepresentation of material information, particularly in industries subject to both SEC and FDA oversight.